Last reviewed · How we verify
TAK-755
TAK-755 is a small molecule that targets the SGLT2 receptor.
TAK-755 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TAK-755 |
|---|---|
| Also known as | rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930, recombinant ADAMTS13, BAX 930, SHP655, rADAMTS13 |
| Sponsor | Takeda |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, TAK-755 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) (PHASE2)
- A Study of TAK-755 in Adults With Acute Ischemic Stroke (PHASE2)
- A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) (PHASE3)
- A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura (PHASE3)
- Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |